Literature DB >> 8970963

A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo.

S Wang1, J M Vos.   

Abstract

We have developed a miniviral vector, pH300, based on the human herpesviruses 1 and 4, herpes simplex virus type 1 (HSV-1), and Epstein-Barr virus (EBV), carrying EBV sequences for plasmid episomal maintenance and HSV-1 sequences for amplification and packaging in multimeric form into HSV-1 capsids in the presence of a helper virus and helper cell line. A reporter gene, the bacterial lacZ gene, which expressed beta-galactosidase, was inserted into the multiple cloning site of pH300 to make pH300-lac. The packaged pH300-lac DNA was very efficient in infecting human cells in tissue culture. The pH300-lac miniviral stock was used to infect in vitro various human cell types derived from breast cancer, lung cancer, and liver cancer. Up to 95% of cells were infected and expressed beta-galactosidase activity after exposure to viral stock at a multiplicity of infection of 3. There was essentially no apparent cytotoxicity after infection of cultured cells in vitro. To test in vivo gene delivery, human liver tumor cells preimplanted subcutaneously in nude mice and injected in situ with pH300-lac showed high efficiency of ectopic gene expression. The pH300 miniviral vector is a simple and effective gene transfer system which shows potential for gene therapy of cancer and inherited diseases.

Entities:  

Mesh:

Year:  1996        PMID: 8970963      PMCID: PMC190931     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Herpes simplex virus amplicon: effect of size on replication of constructed defective genomes containing eucaryotic DNA sequences.

Authors:  A D Kwong; N Frenkel
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

Review 2.  Viral vector systems for gene therapy.

Authors:  D Jolly
Journal:  Cancer Gene Ther       Date:  1994-03       Impact factor: 5.987

Review 3.  Gene therapy for disorders of the nervous system.

Authors:  T Friedmann; H A Jinnah
Journal:  Trends Biotechnol       Date:  1993-05       Impact factor: 19.536

4.  A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells.

Authors:  J Yates; N Warren; D Reisman; B Sugden
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

5.  Characterization of the TRS/IRS origin of DNA replication of herpes simplex virus type 1.

Authors:  N D Stow; E C McMonagle
Journal:  Virology       Date:  1983-10-30       Impact factor: 3.616

Review 6.  Human gene therapy comes of age.

Authors:  A D Miller
Journal:  Nature       Date:  1992-06-11       Impact factor: 49.962

Review 7.  The basic science of gene therapy.

Authors:  R C Mulligan
Journal:  Science       Date:  1993-05-14       Impact factor: 47.728

8.  Regulation of the differentiation of diploid and some aneuploid rat liver epithelial (stemlike) cells by the hepatic microenvironment.

Authors:  W B Coleman; A E Wennerberg; G J Smith; J W Grisham
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

9.  Human artificial episomal chromosomes for cloning large DNA fragments in human cells.

Authors:  T Q Sun; D A Fenstermacher; J M Vos
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

10.  Replication of herpes simplex virus DNA: localization of replication recognition signals within defective virus genomes.

Authors:  D A Vlazny; N Frenkel
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

View more
  17 in total

1.  Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.

Authors:  M Sena-Esteves; Y Saeki; S M Camp; E A Chiocca; X O Breakefield
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

3.  Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector.

Authors:  Qiang Liu; Claudio F Perez; Yaming Wang
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Rapid tumor cell swelling and bursting: beware of collateral damage.

Authors:  Mathieu Lemaire; Mitchell L Halperin
Journal:  Mol Ther       Date:  2009-08       Impact factor: 11.454

5.  An enhanced packaging system for helper-dependent herpes simplex virus vectors.

Authors:  T A Stavropoulos; C A Strathdee
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

7.  Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin.

Authors:  Masataka Suzuki; Kazue Kasai; Yoshinaga Saeki
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors.

Authors:  Anna Paula de Oliveira; Cornel Fraefel
Journal:  Open Virol J       Date:  2010-06-18

9.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.

Authors:  Thomas Heister; Irma Heid; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Herpes Virus Amplicon Vectors.

Authors:  Suresh de Silva; William J Bowers
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.